Andrew Courtwright, MD
Pulmonary Disease · Philadelphia, PANPI 1376770818
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,785 of the $1,824 with a category attached, or 97.9%. Boehringer Ingelheim accounts for 97.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2023 at $1,438 and has fallen 97.3% since, to $38 in 2025.
Across 3 payments — averaging $607.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- Actelion Pharmaceuticals US, Inc.$38
Across 11 payments — averaging $12,982 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$143K
What the payments were for
- Speaking & faculty fees$1,78598%
- Food & beverage$382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 2 | $1,785 |
| Actelion Pharmaceuticals US, Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$1,785
How this compares
$1,824 in reported general payments places this provider in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $19,249 |
| Atovaquone | 18 | $10,103 |
| Valganciclovir Hcl | 21 | $4,587 |
| ValacyclovirValacyclovir Hcl | 77 | $2,648 |
| Tacrolimus | 26 | $2,484 |
| Metoprolol Succinate | 40 | $1,239 |
| Omeprazole | 43 | $884 |
| Azithromycin | 61 | $703 |
| Prednisone | 77 | $686 |
| Gabapentin | 28 | $599 |
| Lansoprazole | 15 | $533 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 72 | $472 |
| Amlodipine Besylate | 56 | $462 |
| Rosuvastatin Calcium | 24 | $438 |
| Famotidine | 48 | $434 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.